Halda Raises $126M toward Precision Cancer Treatments

Halda Therapeutics has secured $126m in a Series B extension financing for its new oncology treatments. The therapy derives from regulated induced proximity targeting chimeras (RIPTACs), which kill cancer cells by disabling essential cell functions. The funds will be used to advance the startup’s first two RIPTAC treatments into clinical trials, with a Phase I trial for metastatic, castration-resistant prostate cancer planned for the first half of 2025.